Mirati to press on with SAPPHIRE study despite mixed results

5 December 2022

US clinical-stage targeted oncology company Mirati Therapeutics (Nasdaq: MRTX) saw its shares close up 5.2% at $96.25 on Friday, after it announced that, based on the results of an interim analysis on overall survival (OS), the registrational Phase III study evaluating sitravatinib in combination with nivolumab (Bristol Myers Squibb’s blockbuster drug Opdivo) in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis.

The decision comes despite the fact that the trial did not hit the pre-planned interim analysis for both superiority and futility in the primary endpoint of OS. The final analysis is expected to be reached in mid-2023.

The news also comes at a time of speculation on a takeover bid for Mirati, which has a current market capitalization of around $5.26 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK